Theriva Biologics, Inc.
Theriva Biologics, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing therapeutics for cancer and related diseases. Its pipeline centers on oncolytic adenovirus programs, including VCN-01, along with earlier-stage assets and manufacturing technologies for viral therapeutics.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaClinical-stage virus-based cancer therapies designed to selectively replicate in tumor cells and enhance anti-tumor response.
Earlier-stage programs such as ribaxamase and SYN-020 targeting antibiotic-related and gastrointestinal diseases.
THERICEL cell-line platform and related know-how for manufacturing viral and gene therapy products.
Out-licensing and partnered development rights for selected programs and technologies.
Asiakkaat
Theriva does not sell commercial medicines at scale; its primary counterparties are clinical trial sites, research collaborators, and potential licensing or development partners. In oncology, the end users are patients with high-unmet-need cancers such as pancreatic cancer, retinoblastoma, and other solid tumors, while future commercialization would depend on hospitals, oncology centers, and specialty distributors.
They administer VCN-01 and other pipeline studies and are essential for patient enrollment and data generation.
They are the intended recipients of oncolytic adenovirus therapies such as VCN-01 in pancreatic cancer and retinoblastoma.
They may license programs such as SYN-020 or collaborate on development and commercialization.
Academic and government partners support platform work such as THERICEL and AAV manufacturing adaptation.
Strategia
Theriva’s strategy is to advance VCN-01 as its lead oncology asset while building optionality through next-generation virus platforms and manufacturing technologies. The company also seeks partnerships and licensing arrangements to fund development, extend its pipeline, and reduce the capital burden of later-stage clinical programs.
VCN-01 is the lead asset and the main source of future value creation.
External funding and commercialization partners can reduce capital needs.
VCN-X and THERICEL can broaden the technology base beyond a single asset.
Maantiede
Theriva is headquartered in the United States but its business is materially international because its core oncology platform originated through the acquisition of Theriva Biologics, S.L. in Spain. Its development work, patents, and collaborations span the U.S. and Europe, and clinical programs may enroll patients across multiple countries depending on trial design.
Riskit
Theriva is exposed to the typical risks of a clinical-stage biotech company: clinical trial failure, regulatory delay, and dependence on external funding. Its concentration in a small number of experimental programs, plus competition from better-capitalized oncology developers, makes execution risk especially important.
- Funding and going-concern pressureVaikutus: KriittinenTodennäköisyys: Korkea
Later-stage trials require substantial capital and no committed financing is assured.
Kohdistuu: Company-wide development budget
- Clinical development failureVaikutus: KorkeaTodennäköisyys: Korkea
VCN-01 and other programs are unproven and depend on trial outcomes.
Kohdistuu - Competitive displacementVaikutus: KorkeaTodennäköisyys: Korkea
Larger biotech and pharma firms can reach approval faster and with more resources.
Kohdistuu: Oncolytic virus and oncology markets
- Regulatory and trial-enrollment riskVaikutus: KeskitasoTodennäköisyys: Korkea
Approval timelines and patient recruitment can slow or stop development programs.
Kohdistuu: Global clinical studies
- Data security and privacy exposureVaikutus: KeskitasoTodennäköisyys: Matala
Clinical trial and patient data are sensitive and subject to privacy rules.
Kohdistuu: U.S. and EU operations
Kirjanpito
Harkinnanvaraiset erätAsset values depend on expected clinical outcomes and future cash flows.
Vaikutus: Can create large non-cash impairment charges
Acquired goodwill is tested for recoverability and can be written down.
Vaikutus: Affects reported earnings and equity
Acquisition-related earnouts require fair-value remeasurement.
Vaikutus: Can introduce volatility in operating results
Clinical and preclinical costs are expensed as incurred.
Vaikutus: Drives period-to-period operating loss volatility
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Ernexa Therapeutics Inc.
ERNAW · Pharmaceutical Preparations
Boundless Bio, Inc.
BOLD · Pharmaceutical Preparations
Acrivon Therapeutics, Inc.
ACRV · Pharmaceutical Preparations
Vincerx Pharma, Inc.
Pharmaceutical Preparations
Vaxcyte, Inc.
PCVX · Biological Products, (No Diagnostic Substances)
Päivitetty: 24.9.2026